Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zsuzsanna Pályi-Krekk"'
Autor:
Yakir Guri, Janos Roszik, Zsuzsanna Pályi-Krekk, Péter Nagy, Reno Debets, Zsolt Sebestyén, Arpad Szoor, Coen Govers, János Szöllosi, György Vereb
Publikováno v:
European Journal of Immunology, 41(5), 1288-1297. Wiley-VCH
T-cell receptors (TCRs) can be genetically modified to improve gene-engineered T-cell responses, a strategy considered critical for the success of clinical TCR gene therapy to treat cancers. TCR:zeta, which is a heterodimer of TCR alpha and beta chai
Autor:
János Szöllosi, Hideyuki Saya, Zsuzsanna Pályi-Krekk, Tamás Kovács, Péter Nagy, Osamu Nagano, Márk Barok
Publikováno v:
Cancer Letters. 263:231-242
Activation of the ErbB family of receptor tyrosine kinases is involved in a range of human cancers. Transmembrane signaling mediated by ErbB proteins is stimulated by peptide growth factors and is blocked by monoclonal antibodies such as trastuzumab
Autor:
Zsuzsanna Pályi-Krekk, Péter Nagy, Ákos Fábián, Miklós Petrás, Zsolt Fazekas, György Vereb, János Szöllosi, Sándor Damjanovich
Publikováno v:
Cytometry Part A. :209-219
� Abstract The role of the expression patterns of proteins involved in oncogenesis can be understood after characterizing their multimolecular interactions. Conventional FRET methods permit the analysis of interaction between two molecular species
Autor:
Janos Roszik, Reno Debets, Péter Nagy, György Vereb, Zsolt Sebestyén, Yakir Guri, Coen Govers, János Szöllősi, Zsuzsanna Pályi-Krekk, Árpád Szöőr
Publikováno v:
European Journal of Immunology. 41
The cover image of this issue consists of a confocal microscopic FRET image showing immunological synapse formation in Jurkat T cells, and is taken from Roszik et al. (pp. 1288–1297). In this article, the authors characterize TCR-ζ, a heterodimer
Although trastuzumab, a recombinant humanised anti-ErbB2 antibody, is widely used in the treatment of breast cancer, neither its mechanism of action, nor the factors leading to resistance are fully understood. We have previously shown that antibody-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75e743a4e381d50fb719b68491c1153a
Autor:
Márk Barok, Jorma Isola, Zsuzsanna Pályi-Krekk, Péter Nagy, István Juhász, György Vereb, Päivikki Kauraniemi, Anita Kapanen, Minna Tanner, János Szöllösi
Trastuzumab is a recombinant antibody drug that is widely used for the treatment of breast cancer. Despite encouraging clinical results, some cancers are primarily resistant to trastuzumab, and a majority of those initially responding become resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e8d37c5d76d8c117a892570fc97ccc7